Cited by 333Cholinesterase and Neurodegenerative DiseasesDementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Farlow, Martin, Anand, Ravi, Messina Jr, John, Hartman, Richard, Veach, Jeffrey·2000·European Neurology

DOI 10.1159/000008243

Open this paper in CoChat — free account

Abstract

The efficacy of a centrally active cholinesterase inhibitor, rivastigmine tartrate (ENA 713; Exelon®), in patients with mild to moderately severe Alzheimer’s disease was evaluated in a 26-week open-label extension of a 26-week, double-blind, placebo-controlled study. By 52 weeks, patients originally treated with 6–12 mg/day rivastigmine had significantly better cognitive function than patients originally treated with placebo.

Integrity signals

Registry

Crossref · 10.1159/000008243

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial Commentary: Another piece of the Alzheimer's jigsaw
Rosler, M., Anand, R., Cicin-Sain, A., Gauthier, S., Agid, Y., Dal-Bianco, P., Stahelin, H. B., Hartman, R., Gharabawi, M., & Bayer, T. (1999) · BMJ · doi:10.1136/bmj.318.7184.633 · Cited by 943
Self-citation
Cholinergic Markers in Elderly Patients With Early Signs of Alzheimer Disease
Davis, K. L. (1999) · JAMA · doi:10.1001/jama.281.15.1401 · Cited by 496
A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
Corey-Bloom, J. (1998) · Medical Entomology and Zoology · Cited by 467
A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration
(1994) · American Journal of Psychiatry · doi:10.1176/ajp.151.3.390 · Cited by 408
Chapter 53: Brain selective inhibition of acetylcholinesterase: a novel approach to therapy for Alzheimer's disease
Enz, A., Amstutz, R., Boddeke, H. W. G. M., Gmelin, G., & Malanowski, J. (1993) · Progress in brain research · doi:10.1016/s0079-6123(08)62429-2 · Cited by 301
Dose-dependent CSF acetylcholinesterase inhibition by SDZ ENA 713 in Alzheimer's disease
Cutler, N. R., Polinsky, R. J., Srarnek, J. J., Enz, A., Jhee, S. S., Mancione, L., Hourani, J., & Zolnouni, P. (2009) · Acta Neurologica Scandinavica · doi:10.1111/j.1600-0404.1998.tb00645.x · Cited by 123
Slowing the progression of Alzheimer disease: methodologic issues.
Leber, P. D. (1997) · PubMed · Cited by 98
Observations and Suggestions on Antidementia Drug Development
Leber, P. D. (1996) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199601031-00009 · Cited by 87
Clinical predictors of course for Alzheimer patients in a longitudinal study: a preliminary report.
Kramer‐Ginsberg, E., Mohs, R. C., Aryan, M., Lobel, D., Silverman, J. M., Davidson, M., & Davis, K. L. (1988) · PubMed · Cited by 83

Flagged first, then by citations

Show all 10 references

Sorted by citations

The cholinergic system in the pathophysiology and treatment of Alzheimer’s disease
Hampel, H., Mesulam, M.-M., Cuello, A. C., Farlow, M. R., Giacobini, E., Grossberg, G. T., Khachaturian, A. S., Vergallo, A., Cavedo, E., Snyder, P. J., et al. (2018) · Brain · doi:10.1093/brain/awy132 · Cited by 1,918
Self-citation
Current and Future Treatments in Alzheimer Disease: An Update
Yiannopoulou, K. G., & Papageorgiou, S. G. (2020) · Journal of Central Nervous System Disease · doi:10.1177/1179573520907397 · Cited by 966
Neurobiology of butyrylcholinesterase
Darvesh, S., Hopkins, D. A., & Geula, C. (2003) · Nature reviews. Neuroscience · doi:10.1038/nrn1035 · Cited by 896
A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD
Winblad, B. G., Engedal, K., Soininen, H. S., Verhey, F. R. J., Waldemar, G., Wimo, A. B., Wetterholm, A.-L., Zhang, R., Haglund, A., Subbiah, P., et al. (2001) · Neurology · doi:10.1212/wnl.57.3.489 · Cited by 721
Current and future treatments for Alzheimer's disease
Yiannopoulou, K. G., & Papageorgiou, S. G. (2013) · Therapeutic Advances in Neurological Disorders · doi:10.1177/1756285612461679 · Cited by 677
Targeting acetylcholinesterase and butyrylcholinesterase in dementia
Lane, R. M., Potkin, S. G., & Enz, A. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005833 · Cited by 654
Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline
Raina, P., Santaguida, P., Ismaila, A., Patterson, C., Cowan, D., Levine, M., Booker, L., & Oremus, M. (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-148-5-200803040-00009 · Cited by 771
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients
Mohs, R. C., Doody, R. S., Morris, J. C., Ieni, J. R., Rogers, S. L., Perdomo, C. A., Pratt, R. D., & for the “312” Study Group (2001) · Neurology · doi:10.1212/wnl.57.3.481 · Cited by 502
Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study
Doody, R. S., Si, G., Sano, M. C., Thomas, R. G., Aisen, P. S. S., Бачурин, С. О., Seely, L., & Hung, D. S.-Y. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61074-0 · Cited by 458
The Perils of Cognitive Enhancement and the Urgent Imperative to Enhance the Moral Character of Humanity
Persson, I., & Savulescu, J. (2008) · Journal of Applied Philosophy · doi:10.1111/j.1468-5930.2008.00410.x · Cited by 414
Cholinesterase Inhibitors for the Treatment of Alzheimer's Disease:
Grossberg, G. T. (2003) · Current Therapeutic Research · doi:10.1016/s0011-393x(03)00059-6 · Cited by 384
Cholinesterase Inhibitors Used in the Treatment of Alzheimer???s Disease
Wilkinson, D. G., Francis, P. T., Schwam, E. M., & Payne-Parrish, J. (2004) · Drugs & Aging · doi:10.2165/00002512-200421070-00004 · Cited by 367
Rosiglitazone Monotherapy in Mild-to-Moderate Alzheimer’s Disease: Results from a Randomized, Double-Blind, Placebo-Controlled Phase III Study
Gold, M., Alderton, C., Zvartau-Hind, M., Egginton, S., Saunders, A. M., Irizarry, M., Craft, S., Landreth, G., Linnamägi, Ü., & Sawchak, S. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000318845 · Cited by 361
Current Pharmacotherapy for Alzheimer's Disease
Lleó, A., Greenberg, S. M., & Growdon, J. H. (2005) · Annual Review of Medicine · doi:10.1146/annurev.med.57.121304.131442 · Cited by 347
Galantamine — a Novel Cholinergic Drug with a Unique Dual Mode of Action for the Treatment of Patients with Alzheimer's Disease
Lilienfeld, S. (2002) · CNS Drug Reviews · doi:10.1111/j.1527-3458.2002.tb00221.x · Cited by 309
Current and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309
Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis.
Lanctôt, K. L., Herrmann, N., Yau, K. K., Khan, L. R., Liu, B. A., Loulou, M., & Einarson, T. R. (2003) · PubMed Central · Cited by 303
Benefits of cognitive-motor intervention in MCI and mild to moderate Alzheimer disease
Olazarán, J., Muñiz, R., Reisberg, ‌., Peña‐Casanova, J., del Ser, T., Cruz-Jentoft, A. J., Serrano, P., Navarro, E., de la Rocha, M. L. G., Frank, A., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000147478.03911.28 · Cited by 294
Cholinesterase Inhibitors for Alzheimer??s Disease
Grutzendler, J., & Morris, J. C. (2001) · Drugs · doi:10.2165/00003495-200161010-00005 · Cited by 273
Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease
Lopez, O. L., Becker, J. T., Wahed, A. S., Saxton, J., Sweet, R. A., Wolk, D. A., Klunk, W., & DeKosky, S. T. (2009) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.2008.158964 · Cited by 266
Advances in the Treatment of Alzheimer’s Disease: Benefits of Dual Cholinesterase Inhibition
Ballard, C. G. (2002) · European Neurology · doi:10.1159/000047952 · Cited by 261
PHARMACEUTICAL BENEFITS ADVISORY COMMITTEE
(1958) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.1958.tb58406.x · Cited by 255
Recent advances on drug development and emerging therapeutic agents for Alzheimer’s disease
Athar, T., Balushi, K. A. A., & Khan, S. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06512-9 · Cited by 273
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Does Donepezil Treatment Slow the Progression of Hippocampal Atrophy in Patients With Alzheimer’s Disease?
Hashimoto, M., Kazui, H., Matsumoto, K., Nakano, Y., Yasuda, M., & Mori, E. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.4.676 · Cited by 241
Long-term course and effectiveness of combination therapy in Alzheimer disease
Atri, A., Shaughnessy, L. W., Locascio, J. J., & Growdon, J. H. (2008) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31816653bc · Cited by 230
Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period
Bullock, R. A., Touchon, J., Bergman, H., Gambina, G., He, Y., Rapatz, G., Nagel, J., & Lane, R. M. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x56565 · Cited by 228
Pharmacologic treatments of dementia
Bonner, L. T., & Peskind, E. R. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00007-x · Cited by 226
CSF biomarkers predict a more malignant outcome in Alzheimer disease
Wallin, A., Blennow, K., Zetterberg, H., Londos, E., Minthon, L., & Hansson, O. (2010) · Neurology · doi:10.1212/wnl.0b013e3181dd4dd8 · Cited by 223
Effective Pharmacologic Management of Alzheimer’s Disease
Farlow, M. R., & Cummings, J. L. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.08.036 · Cited by 227
Self-citation
Donepezil treatment of patients with MCI
Doody, R. S., Ferris, S. H., Salloway, S., Sun, Y., Goldman, R. S., Watkins, W. E., Xu, Y., & Murthy, A. K. (2009) · Neurology · doi:10.1212/01.wnl.0000344650.95823.03 · Cited by 212
Use of Cholinesterase Inhibitors in Clinical Practice: Evidence-Based Recommendations
Cummings, J. L. (2003) · American Journal of Geriatric Psychiatry · doi:10.1097/00019442-200303000-00004 · Cited by 203
DONEPEZIL TREATMENT OF PATIENTS WITH MCI: A 48-WEEK RANDOMIZED, PLACEBO- CONTROLLED TRIAL
Crane, P. K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181bd6c25 · Cited by 194
Benzofuran-Based Hybrid Compounds for the Inhibition of Cholinesterase Activity, β Amyloid Aggregation, and Aβ Neurotoxicity
Rizzo, S., Rivière, C., Piazzi, L., Bisi, A., Gobbi, S., Bartolini, M., Andrisano, V., Morroni, F., Tarozzi, A., Monti, J., et al. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm8002747 · Cited by 191
Reimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality
Xu, H., Garcia-Ptacek, S., Jönsson, L., Wimo, A., Nordström, P., & Eriksdotter, M. (2021) · Neurology · doi:10.1212/wnl.0000000000011832 · Cited by 182
Mild cognitive impairment: An opportunity to identify patients at high risk for progression to Alzheimer's disease
Levey, A. I., Lah, J. J., Goldstein, F. C., Steenland, K., & Bliwise, D. L. (2006) · Clinical Therapeutics · doi:10.1016/j.clinthera.2006.07.006 · Cited by 187
3-Year Study of Donepezil Therapy in Alzheimer’s Disease: Effects of Early and Continuous Therapy
Winblad, B. G., Wimo, A. B., Engedal, K., Soininen, H. S., Verhey, F. R. J., Waldemar, G., Wetterholm, A.-L., Haglund, A., Zhang, R., & Schindler, R. J. (2006) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000091790 · Cited by 176
Methods to improve the detection of mild cognitive impairment
Shankle, W. R., Romney, A. K., Hara, J., Fortier, D., Dick, M. B., Chen, J., Chan, T., & Sun, X. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501157102 · Cited by 169
The Cognitive Benefits of Galantamine Are Sustained for at Least 36 Months: A Long-term Extension Trial
Raskind, M. A., Peskind, E. R., Truyen, L., Kershaw, P., & Damaraju, C. V. (2004) · Archives of Neurology · doi:10.1001/archneur.61.2.252 · Cited by 167
Recent advances in acetylcholinesterase Inhibitors and Reactivators: an update on the patent literature (2012-2015)
McHardy, S. F., Wang, H.-Y. L., McCowen, S. V., & Valdez, M. C. (2016) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2017.1272571 · Cited by 167
Cholinesterase inhibitors in the treatment of dementia.
Ellis, J. M. (2005) · PubMed · Cited by 161
Clinical practice with anti-dementia drugs: a consensus statement from British Association for Psychopharmacology
Burns, A. S., & O'Brien, J. T. (2006) · Journal of Psychopharmacology · doi:10.1177/0269881106068299 · Cited by 157
Acetylcholinesterase and Its Inhibition in Alzheimer Disease
Lane, R. M., Kivipelto, M., & Greig, N. H. (2004) · Clinical Neuropharmacology · doi:10.1097/00002826-200405000-00011 · Cited by 149
Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study
Bakchine, S., & Loft, H. (2007) · Journal of Alzheimer s Disease · doi:10.3233/jad-2007-11409 · Cited by 135
Animal models of Alzheimer disease: historical pitfalls and a path forward
Cavanaugh, S. E. (2014) · ALTEX · doi:10.14573/altex.1310071 · Cited by 132
Pharmacotherapy of Alzheimer's disease: is there a need to redefine treatment success?
Winblad, B. G., Brodaty, H., Gauthier, S. G., Morris, J. C., Orgogozo, J., Rockwood, K. J., Schneider, L. S. S., Takeda, M., Tariot, P. N., & Wilkinson, D. G. (2001) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.496 · Cited by 125
A review of rivastigmine: A reversible cholinesterase inhibitor
Williams, B. R., Nazarians, A., & Gill, M. A. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80160-1 · Cited by 122
Current therapeutic targets for the treatment of Alzheimer’s disease
Grill, J. D., & Cummings, J. L. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.29 · Cited by 123
Early Alzheimer's Disease
Kawas, C. H. (2003) · New England Journal of Medicine · doi:10.1056/nejmcp022295 · Cited by 115
Efficacy and safety of donepezil in patients with more severe Alzheimer's disease: a subgroup analysis from a randomized, placebo‐controlled trial
Feldman, H., Gauthier, S. G., Hecker, J. R., Vellas, B. J., Xu, Y., Ieni, J. R., & Schwam, E. M. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1325 · Cited by 112
Management of Alzheimer's Disease
Grossberg, G. T., & Desai, A. K. (2003) · The Journals of Gerontology Series A · doi:10.1093/gerona/58.4.m331 · Cited by 110
Economic considerations in the management of Alzheimer's disease
Zhu, C. W., & Sano, M. (2006) · Clinical Interventions in Aging · doi:10.2147/ciia.2006.1.2.143 · Cited by 111
Long-term effects of rivastigmine in moderately severe Alzheimer's disease
Doraiswamy, P. M., Krishnan, K., Anand, R., Sohn, H., Danyluk, J., Hartman, R. D., & Veach, J. (2002) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(01)00326-8 · Cited by 108
Self-citation
Rivastigmine in subcortical vascular dementia
Moretti, R., Torre, P., Antonello, R. M., Cazzato, G., & Bava, A. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00280-0 · Cited by 107
Cognition, Function, and Caregiving Time Patterns in Patients With Mild-to-Moderate Alzheimer Disease
Feldman, H., van Baelen, B., Kavanagh, S. M., & Torfs, K. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000157065.43282.bc · Cited by 107
Alteration of a Clinically Meaningful Outcome in the Natural History of Alzheimer's Disease by Cholinesterase Inhibition
López, O. L., Becker, J. T., Saxton, J. A., Sweet, R. A., Klunk, W. E., & DeKosky, S. T. (2004) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.2005.53015.x · Cited by 105
Cortical sources of resting state electroencephalographic rhythms in Parkinson’s disease related dementia and Alzheimer’s disease
Babiloni, C., Pandis, M. F. D., Vecchio, F., Buffo, P., Sorpresi, F., Frisoni, G. B., & Rossini, P. M. (2011) · Clinical Neurophysiology · doi:10.1016/j.clinph.2011.03.029 · Cited by 104
A Clinical Overview of Cholinesterase Inhibitors in Alzheimer’s Disease
Farlow, M. R. (2002) · International Psychogeriatrics · doi:10.1017/s1041610203008688 · Cited by 100
Self-citation
The ABC of Alzheimer’s Disease: Cognitive Changes and Their Management in Alzheimer’s Disease and Related Dementias
Corey‐Bloom, J. (2002) · International Psychogeriatrics · doi:10.1017/s1041610203008664 · Cited by 97
Cortical Sources of Resting State EEG Rhythms are Sensitive to the Progression of Early Stage Alzheimer's Disease
Babiloni, C., Lizio, R., Percio, C. D., Marzano, N., Soricelli, A., Salvatore, E., Ferri, R., Cosentino, F., Tedeschi, G., Montella, P., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-121750 · Cited by 102
Cerebral blood flow and cognitive responses to rivastigmine treatment in Alzheimer’s disease
Venneri, A., Shanks, M. F., Staff, R. T., Pestell, S. J., Forbes‐McKay, K., Gemmell, H. G., & Murray, A. D. (2002) · Neuroreport · doi:10.1097/00001756-200201210-00020 · Cited by 98
Effectiveness of antidementia drugs in delaying Alzheimer's disease progression
Rountree, S. D., Atri, A., Lopez, O. L., & Doody, R. S. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.01.002 · Cited by 97
The role of general practitioners in the diagnosis and treatment of Alzheimer’s disease: a multinational survey
Wilkinson, D., Stave, C., Keohane, D., & Vincenzino, O. (2004) · Journal of International Medical Research · doi:10.1177/147323000403200207 · Cited by 99
Health care utilization and costs of Alzheimer's disease: the role of co-morbid conditions, disease stage, and pharmacotherapy.
Fillit, H. M., Hill, J. W., & Futterman, R. (2002) · PubMed · Cited by 92
Current concepts in therapeutic strategies targeting cognitive decline and disease modification in Alzheimer’s disease
Jacobsen, J. S., Reinhart, P. H., & Pangalos, M. N. (2005) · NeuroRx · doi:10.1602/neurorx.2.4.612 · Cited by 94
Evaluation of Rivastigmine in Alzheimer’s Disease
Nguyen, K. T., Hoffman, H. L., Chakkamparambil, B., & Grossberg, G. T. (2020) · Neurodegenerative Disease Management · doi:10.2217/nmt-2020-0052 · Cited by 89
Memantine Treatment in Patients with Mild to Moderate Alzheimer's Disease: Results of a Randomised, Double-Blind, Placebo-Controlled 6-Month Study
Bakchine, S., & Loft, H. (2008) · Journal of Alzheimer s Disease · doi:10.3233/jad-2008-13110 · Cited by 88
Cognitive performance in patients with Alzheimer's disease receiving cholinesterase inhibitors for up to 5 years
Bullock, R. M., & Dengiz, A. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00562.x · Cited by 87
Defining optimal treatment with cholinesterase inhibitors in Alzheimer's disease
Small, G. W., & Bullock, R. A. (2010) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.03.016 · Cited by 83
Neuroprotective strategies in Alzheimer’s disease
Longo, F. M., & Massa, S. M. (2004) · NeuroRx · doi:10.1602/neurorx.1.1.117 · Cited by 83
Nicotinic acetylcholine receptors: an overview on drug discovery
D’hoedt, D., & Bertrand, D. (2009) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220902841045 · Cited by 79
Longitudinal PET evaluation of cerebral glucose metabolism in rivastigmine treated patients with mild Alzheimer’s disease
Stefanova, E. D., Wall, A., Almkvist, O., Nilsson, A., Forsberg, A., Långström, B., & Nordberg, A. K. (2005) · Journal of Neural Transmission · doi:10.1007/s00702-005-0312-6 · Cited by 79
Carbamate Derivatives of Indolines as Cholinesterase Inhibitors and Antioxidants for the Treatment of Alzheimer’s Disease
Yanovsky, I., Finkin-Groner, E., Zaikin, A., Lerman, L., Shalom, H., Zeeli, S., Weill, T., Ginsburg, I., Nudelman, A., & Weinstock, M. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301411g · Cited by 77
Current and Emerging Pharmacological Treatment Options for Dementia
Ringman, J. M., & Cummings, J. L. (2006) · Behavioural Neurology · doi:10.1155/2006/315386 · Cited by 77
Current Therapeutic Options for Alzheimers Disease
Lleó, A. (2007) · Current Genomics · doi:10.2174/138920207783769549 · Cited by 77
CSF tau protein andβ‐amyloid (1–42) in Alzheimer's disease diagnosis: discrimination from normal ageing and other dementias in the Greek population
Kapaki, E., Paraskevas, G. P., Zalonis, I., & Zournas, C. (2003) · European Journal of Neurology · doi:10.1046/j.1468-1331.2003.00562.x · Cited by 80
Long-Term Treatment of Alzheimer Disease
Winblad, B. G., & Jelić, V. (2004) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000127495.10774.a4 · Cited by 76
The effect of telemedicine on cognitive decline in patients with dementia
Kim, H. S., Jhoo, J. H., & Jang, J. (2015) · Journal of Telemedicine and Telecare · doi:10.1177/1357633x15615049 · Cited by 75
Analysis of Outcome in Retrieved Dropout Patients in a Rivastigmine vs Placebo, 26-Week, Alzheimer Disease Trial
Farlow, M. R., Potkin, S. G., Koumaras, B., Veach, J., & Mirski, D. F. (2003) · Archives of Neurology · doi:10.1001/archneur.60.6.843 · Cited by 72
Self-citation
How long can patients with mild or moderate Alzheimer’s dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population‐based study
Sun, Y., Lai, M., Lu, C. ‐., & Chen, R. ‐. (2008) · European Journal of Neurology · doi:10.1111/j.1468-1331.2007.02049.x · Cited by 71
Role of Fluid Biomarkers and PET Imaging in Early Diagnosis and its Clinical Implication in the Management of Alzheimer’s Disease
Hameed, S., Fuh, J., Senanarong, V., Ebenezer, E. G. M., Looi, I., Dominguez, J. C., Park, K. W., Karanam, A. K., & Simon, O. (2020) · Journal of Alzheimer s Disease Reports · doi:10.3233/adr-190143 · Cited by 69
Rivastigmine in the treatment of patients with Alzheimer's disease
Müller, T. H. (2007) · Neuropsychiatric Disease and Treatment · doi:10.2147/nedt.2007.3.2.211 · Cited by 67
Cholinesterase Inhibitors May Not Benefit Mild Cognitive Impairment and Mild Alzheimer Disease Dementia
Han, J.-Y., Besser, L. M., Xiong, C., Kukull, W. A., & Morris, J. C. (2019) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000291 · Cited by 70
Inactivation of the human brain muscarinic acetylcholine receptor by oxidative damage catalyzed by a low molecular weight endogenous inhibitor from Alzheimer’s brain is prevented by pyrophosphate analogs, bioflavonoids and other antioxidants
Fawcett, J. R., Bordayo, E. Z., Jackson, K., Liu, H., Peterson, J., Svitak, A. L., & Frey, W. H. (2002) · Brain Research · doi:10.1016/s0006-8993(02)02981-5 · Cited by 66
A 12-Month Study of the Efficacy of Rivastigmine in Patients with Advanced Moderate Alzheimer’s Disease
Karaman, Y., Erdoğan, F. F., Köseoğlu, E., Turan, T., & Ersoy, A. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000080972 · Cited by 66
Long‐term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with Alzheimer's disease
Zhu, C. W., Livote, E. E., Scarmeas, N., Albert, M., Brandt, J., Blacker, D., Sano, M. C., & Stern, Y. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.09.015 · Cited by 67
Digitally translated Self-Administered Gerocognitive Examination (eSAGE): relationship with its validated paper version, neuropsychological evaluations, and clinical assessments
Scharre, D. W., Chang, S. I., Nagaraja, H. N., Vrettos, N. E., & Bornstein, R. A. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0269-3 · Cited by 66
An Artificial Neural Network Integrated Pipeline for Biomarker Discovery Using Alzheimer's Disease as a Case Study
Zafeiris, D., Rutella, S., & Ball, G. (2018) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2018.02.001 · Cited by 66
Long-Term Cholinesterase Inhibitor Treatment of Alzheimer???s Disease
Johannsen, P. (2004) · CNS Drugs · doi:10.2165/00023210-200418120-00001 · Cited by 65
Inhibition of acetylcholinesterase in CSF versus brain assessed by 11C-PMP PET in AD patients treated with galantamine
Darreh‐Shori, T., Kadir, A., Almkvist, O., Grut, M., Wall, A., Blomquist, G., Eriksson, B., Långström, B., & Nordberg, A. K. (2006) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2006.09.020 · Cited by 63
Drug Persistency Patterns for Patients Treated With Rivastigmine or Donepezil in Usual Care Settings
Mauskopf, J., Paramore, C., Lee, W. C., & Snyder, E. H. (2005) · Journal of Managed Care Pharmacy · doi:10.18553/jmcp.2005.11.3.231 · Cited by 62
Realistic Expectations: The Management of Severe Alzheimer Disease
Bullock, R. A., & Hammond, G. (2003) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200307003-00004 · Cited by 61
Advances on Therapeutic Strategies for Alzheimer’s Disease: From Medicinal Plant to Nanotechnology
Hassan, N. A., Alshamari, A. K., Hassan, A. A., Elharrif, M. G., Alhajri, A. M., Sattam, M., & Khattab, R. R. (2022) · Molecules · doi:10.3390/molecules27154839 · Cited by 68
Defining the Role of the Caregiver in Alzheimer??s Disease Treatment
Brodaty, H., & Green, A. (2002) · Drugs & Aging · doi:10.2165/00002512-200219120-00001 · Cited by 60
Four Decades of Research in Alzheimer’s Disease (1975–2014): A Bibliometric and Scientometric Analysis
Serrano‐Pozo, A., Aldridge, G. M., & Zhang, Q. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170184 · Cited by 59
Treatment Guidelines for Alzheimer's Disease
Geldmacher, D. (2007) · The Primary Care Companion to The Journal of Clinical Psychiatry · doi:10.4088/pcc.v09n0205 · Cited by 58
The costs of vascular dementia
Fillit, H. M., & Hill, J. W. (2002) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00257-5 · Cited by 58
The Pharmacoeconomics of Cognitive Enhancers in Moderate to Severe Alzheimerʼs Disease
Cappell, J., Herrmann, N., Cornish, S., & Lanctôt, K. L. (2010) · CNS Drugs · doi:10.2165/11539530-000000000-00000 · Cited by 57

Authors: Farlow, M., Anand, R., Messina Jr, J., Hartman, R., & Veach, J.
Affiliations: Indiana University Indianapolis (US)
ORCID: Farlow, Martin
Anand, Ravi
Hartman, Richard
Venue: European Neurology
Publisher: S. Karger AG
Published: 2000
Volume: 44
Issue: 4
Pages: 236-241
ISSN: 0014-3022 (ISSN-L)
1421-9913
DOI: 10.1159/000008243
OpenAlex: W2076676029
Cited by: 332
References: 10
Citations by year: 2026: 6 · 2025: 6 · 2024: 7 · 2023: 9 · 2022: 10 · 2021: 8 · 2020: 6 · 2019: 7 · 2018: 5 · 2017: 5 · 2016: 8 · 2015: 4 · 2014: 3 · 2013: 9 · 2012: 7
FWCI: 15.52
Type: journal article
Language: en
Open access: closed
Licence: www.karger.com/Services/SiteLicenses (vor)
www.karger.com/Services/SiteLicenses (tdm)
Locations: European Neurology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Keywords: rivastigmine, Alzheimer's disease, cholinesterase inhibitors, cognitive function, open-label extension, long-term efficacy
MeSH terms: Rivastigmine, Age Factors, Aged, Alzheimer Disease, Carbamates, Cholinesterase Inhibitors, Cognition, Dose-Response Relationship, Drug, Double-Blind Method, Humans, Time Factors, Treatment Outcome, Disease Progression, Phenylcarbamates

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A 52-Week Study of the Efficacy of Rivastigmine in Patients with Mild to Moderately Severe Alzheimer’s Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks